The results of Figure 2 clearly show that the expression of the inflammatory chemokines CCL2 and CCL5 remained high and constant in the tumor cells of DCIS, IDC-no-relapse and IDC-with-relapse patients. This evidence concerns the gene CCL2 and ductal breast carcinoma in situ.